Naldini, Luigi
Article History
Received: 15 April 2015
Accepted: 24 August 2015
First Online: 14 October 2015
Competing interests
: L.N. is listed as an inventor on pending and issued patents on lentiviral-vector technology, microRNA-regulated vectors and targeted genome editing that were filed by the Salk Institute for Biological Studies, Cell Genesys, the Telethon Foundation and the San Raffaele Scientific Institute. As the director of TIGET, L.N. is involved in a strategic alliance for the development (to marketing authorization) of HSC-based gene therapies for some rare diseases with GlaxoSmithKline (GSK), which licensed metachromatic leukodystrophy and WAS gene therapies in 2014 and became the financial sponsor of the trials. L.N. has established research collaborations on targeted genome editing in HSCs with Sangamo BioSciences and on lentiviral gene therapy of haemophilia with Biogen. L.N. is a founder, owns equity in and chairs the scientific advisory board of Genenta Science, a biotechnology start-up company that aims to develop gene therapy for tumours using tumour-infiltrating monocytes.